RBN-2397 is a highly potent and selective, orally bioavailable PARP7 inhibitor that competes with NAD+ across multiple species, exhibiting an IC50 below 3 nM. It is a valuable research tool for studying PARP7s role in cancer biology and has demonstrated antitumor activity in both cellular assays and in vivo models.